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Increasing evidence supports the anti-inflammatory role of estrogens in Multiple Sclerosis
(MS), originating from the observation of reduction in relapse rates among women with
MS during pregnancy, but the molecular mechanisms are still not completely understood.
Using an integrative data analysis, we identified T helper (Th) 17 and T regulatory (Treg)
cell-type-specific regulatory regions (CSR) regulated by estrogen receptor alpha (ERα).
These CSRs were validated in polarized Th17 from healthy donors (HD) and in peripheral
blood mononuclear cells, Th17 and Treg cells from relapsing remitting (RR) MS patients
and HD during pregnancy. 17β-estradiol induces active histone marks enrichment at
Forkhead Box P3 (FOXP3)-CSRs and repressive histone marks enrichment at RAR
related orphan receptor C (RORC)-CSRs in polarized Th17 cells. A disease-associated
epigenetic profile was found in RRMS patients during pregnancy, suggesting a FOXP3
positive regulation and a RORC negative regulation in the third trimester of pregnancy.
Altogether, these data indicate that estrogens act as immunomodulatory factors on the
epigenomes of CD4+ T cells in RRMS; the identified CSRs may represent potential
biomarkers for monitoring disease progression or new potential therapeutic targets.
Keywords: pregnancy, epigenetic profile, RORC, FOXP3, Th17, Treg, multiple sclerosis, ERα
INTRODUCTION
Multiple Sclerosis (MS) is an autoimmune disease characterized by chronic inflammation of the
central nervous system (CNS) affecting 2.5 million people worldwide, with a female/male sex
ratio of 3:1 (1, 2). Pro-inflammatory T helper (Th) 17 cells are required for the pathogenesis of
MS (3, 4) and its mouse model, the experimental autoimmune encephalomyelitis (EAE), whereas
CD4+Foxp3+ regulatory T cells (Treg), crucial for preventing autoimmunity, are defective in
numbers and functions (5). Intriguingly, the female sex hormone estrogen is protective in MS:
it exerts potent effects on immune cells and in the CNS during pregnancy, especially in the third
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trimester when they peak and the most pronounced decrease
in the relapse rate occurs (6). This potent, short-term beneficial
effect of pregnancy is then followed by a temporary rebound of
disease activity post-partum, probably due to the fall of estrogen
serum concentration (7).
The role of estrogen-induced immunomodulation is well-
demonstrated both on innate immune cells and on adaptive
immune cells (8), however little is known about the molecular
mechanism underlying its action on the immune system.
Estrogens act by binding Estrogen Receptors (ER) α and β
that, functioning as ligand-activated transcription factors, bind
specific DNA sequences, associate chromatin remodelers and
transcriptional factors, and therefore regulate a broad range of
estrogen-responsive genes. Among T lymphocytes, CD4+ T cells
express higher levels of ERα than ERβ (9) and ERα signaling
is required for estrogen-mediated regulation of CD4+ T cell
subsets and protection against EAE (10, 11). In the EAE model,
estrogens have been shown to have an anti-inflammatory effect
by inhibiting CD4+ T cells expansion, decreasing autoantigen-
specific Th1 and Th17 cells (12, 13) and increasing proportion
of Treg cells (14, 15). In MS patients, the protective effect
of estrogens has been reported in a pivotal trial (16, 17) and
currently, large placebo-controlled clinical trials of estrogen
therapy in MS are still ongoing (18).
CD4+ T cells, after being activated, differentiate into distinct
effector subsets, characterized by the expression of specific
Transcription Factors (TF), cytokines, cytokine receptors, and
surface molecules that drive different immunomodulatory
features (19). Each cell type has its own unique chromatin
landscape that defines cell identity and its specific functions.
However, these cells retain the ability to change their identity
and adapt their functions upon new polarizing environments
that act on cell-type specific epigenetic features. Interestingly,
the balance between Th17 and Treg cells, that have a central
role in MS outcome (20), depends on epigenetic dynamics (21).
These pivotal regulatory nodes can divert T cell functions toward
inflammatory or regulatory state reprogramming T cells and
modulating immune response (22, 23).
Epigenomic profiling is used to identify the chromatin
status at cis-regulatory regions, promoters and enhancers. The
analysis of epigenomic data led to the identification of clusters
of enhancers in close genomic proximity, defined as Super
Enhancers (SEs), which play an essential role in defining cell
identity (24). The identification of SEs is usually performed
by looking at the enrichment of different epigenetic features
such as lysine 27 acetylation of histone H3 (H3K27ac), the
binding of p300 and the binding of master regulator TFs
(25, 26). The combinatorial effect of histone marks defines the
histone code by providing a more detailed view of epigenomic
status at the genomic regulatory regions, and allows better
characterization of active sites of transcriptional regulation (27).
Whereas, mRNA expression profiling provides a snapshot of
the current state of a cell, the understanding of the epigenetic
regulation can give a perspective on how this conformation
has been reached and could potentially change (28). Immune
system adaptation is driven by molecular circuitry in which cell-
type specific regulatory regions represent a central component.
These core-enhancers are associated with lineage-specific TF
binding and they are downstream target of cytokines pathways.
Therefore, these genomic regions represent a key regulatory
hub of cell-identity and they may be involved in cell plasticity
dynamics (29).
In the present study, we used an integrative approach to
reconstruct a regulatory network of Th17- and Treg-specific TFs.
The network defined using a set of cell type-specific genomic
regulatory regions, allowed us to extract putative ERα-regulated
enhancers, which are active in these two CD4+ subtypes.
Among the identified TFs, RORC, and FOXP3 emerged as
candidate targets of estrogenic signaling in Th17 and Treg cells,
respectively. We evaluated 17β-estradiol (E2)-induced epigenetic
changes at cell type-specific regulatory regions of RORC and
FOXP3 loci in Th17 polarizing Peripheral Blood Mononuclear
Cells (PBMC). Thus, we monitored the epigenetic status of these
regions in PBMCs and purified Th17 and Treg cells derived
from RRMS patients and healthy donors during pregnancy. We
found that these genomic regions have MS-associated epigenetic
signature in cells from pregnant individuals suggesting that they
could constitute key regulatory hubs acting as switchers between
Th17 and Treg cells in the pathological condition.
MATERIALS AND METHODS
Study Design
This study was designed to investigate the epigenetic profile of
Th17 and Treg cells inMS patients during pregnancy. To identify
Th17 and T regulatory CSR regulated by ERα, an integrative data
analysis was performed on public data sets: first, SEs prediction
was combined with chromatin states analysis, and then, a core
regulatory network in Th17 and Treg cells based on CSRs and
putative ERα binding was reconstructed. Specifically, we focused
on RORC and FOXP3 CSRs.
Therefore, peripheral blood of RRMS patients during the
third trimester of pregnancy (T3) and in the postpartum period
(pp) were collected and analyzed. The institutional review board
of each participating center approved the study design and all
subjects gave written informed consent. PBMCs from HD were
activated under Th17 polarizing condition to test the effects of E2
treatment at pregnancy concentration on the selected CSRs, the
mRNA levels of RORC and FOXP3 and the percentage of Th17
and Treg cells. PBMCs from pregnant RRMS patients and HD
were analyzed by FACS for Th17 and Treg cells and by Chromatin
Immuno Precipitation (ChIP) followed by quantitative PCR
(qPCR) for CSRs. The numbers of independent experiments or
individuals are given in each figure legend.
Super Enhancers Prediction
SEs were identified using Rank Ordering of Super
Enhancers (ROSE) algorithm (26) in default settings.
CD4+CD25–CD45RA+ cells (Naive T), CD4+CD25–
T cells (Th), CD4+CD25–IL17+ T cells (Th17), and
CD4+CD25+CD45RA+ T cells (Treg) SEs have been
defined applying ROSE algorithm on H3K27ac ChIP followed
by sequencing (-Seq) datasets of Naive (GSM773004),
Th (GSM997239), Th17 (GSM772987), and Treg cells
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(GSM1056941). Significant H3K27ac ChIP-Seq peaks were
defined using MACS2 algorithm version 2.1.0 (30) applied
in default settings. Input ChIP-Seq datasets were used as
background models for SE and enhancer calling. The list
of significant ChIP-Seq peaks was used as input for ROSE
algorithm.
SNPs Analysis
SNPs associated with 41 different diseases were retrieved from
GWAS database v2 (31). SNPs were overlapped with SEs from
earlier analysis. Enrichment scores were computed generating
1,000,000 random regions of the same length and calculated as:
p− value =
1+ n◦ of times Npermi ≥ Nobs
1+ n◦ of permutations
with:
Nobs = Number of trait-associated SNPs observed to fall in
our dataset
Npermi=Number of trait-associated SNPs observed to fall in
a randomly generated dataset (n= 1,000,000).
Chromatin States Analysis
Genome segmentation data from Roadmap Epigenomics Project
(32) were retrieved from the project website (http://egg2.wustl.
edu/roadmap/web_portal) considering the 25-chromatin states
model defined on imputed epigenomic data from 127 different
cell types. The model is based on imputed data for 12 epigenetic
marks (H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K27ac,
H4K20me1, H3K79me2, H3K36me3, H3K9me3, H3K27me3,
H2A.Z, and DNase accessibility) predicted by ChromHMM
(27). These data report the genomic segmentation computed
on each cell type. The segmentation consists in consecutive
non-overlapping 200 bp genomic regions annotated with
the predicted chromatin state. Segmentation data related to
“E039—Primary CD25– CDRA45+ Naive T cells,” “E043—
Primary CD25– Th cells,” “E042—Primary IL17+ PMA-I
stimulated Th cells,” “E044—Primary CD25+ regulatory T
cells” were extracted. The identification of regulatory regions
was performed by considering the chromatin states associated
with an emission parameter of H3K27ac and H3K4me1 ≥75.
Using this threshold, six chromatin states (2_PromU, 9_TxReg,
10_TxEnh5′, 13_EnhA1, 14_EnhA2, 15_EnhAF) were defined as
active regulatory states. The segments classified in these states
were extracted from the CD4+ segmentation data using an
in-house Python script. Then, consecutive genomic segments
classified as regulatory were merged defining the regulatory
regions set for each CD4+ subtype. To distinguish regulatory
regions according to their level of activity among CD4+
subtypes, the chromatin state predicted in each 200 bp fragment
composing regulatory regions was compared among CD4+ cell
subtypes. If more than half of the fragments within a merged
region were classified as active regulatory regions in a specific
CD4+ subtype only, the entire region was classified as ARRs in
that specific CD4+ subtype. SE-ARRs were obtained overlapping
ARRs and SEs using the intersect function of Bedtools suite (33).
Histone Marks Enrichment Analysis
The evaluation of histone marks enrichment within ARRs,
SE-ARRs, and CSRs has been performed overlapping selected
regions with ChIP-Seq dataset retrieved from Roadmap project
using the intersect function of Bedtools suite (33). The list of
datasets used for this analysis is in Table S1G. Histone marks
enrichment in ARRs and SE-ARRs was computed as the mean
of replicates over the mean of input datasets in each cell
subtype. Histonemarks enrichment in CSRs associated genes was
computed as the mean of the enrichment in each CSR associated
to a single gene.
Gene Ontology Analysis
Functional and ontological enrichment analysis of genes mapped
in proximity of SEs and SE-ARRs was performed using the
Genomic Regions Enrichment of Annotations Tool (GREAT) in
default mode (34).
RNA-Seq Analysis
Twenty-five PolyA+ RNA-Seq experiments performed on
five CD4+ subtypes isolated from healthy donors were
re-analyzed (ArrayExpress Archive of Functional Genomics
Data experiment accession: E-MTAB-2319) (35). In detail,
sequencing reads of the five replicates of CD4+ Naïve
cells (CD4+CCR7+CD45RA+CD45RO–), CD4+ Th1 cells
(CD4+CXCR3+), CD4+ Th2 cells (CD4+CRTH2+CXCR3–),
CD4+ Th17 (CD4+CCR6+CD161+CXCR3–), and CD4+ Treg
cells (CD4+CD127–CD25+) were retrieved and considered for
this analysis. Reads were mapped using TopHat v2 (36). The
hg19 human genome assembly was used as a reference genome
while Gencode v19 as a reference set of gene annotations.
Read count was performed using FeatureCounts algorithm
and read count tables were normalized with DESeq2 package
(37, 38). Normalized read counts were converted to fragments
per kilobase of exons per million fragments mapped (FPKM)
considering the length of the longest isoform of each gene
and the millions of reads. Genes with FPKM > 1 in all
five biological replicates available for a CD4+ subtype were
considered expressed in that specific subtype. SEs were annotated
to CD4+ expressed genes whose TSS was mapped within a
distance of 100 Kbp from the center of the nearest SE. Differential
expression analysis was performed using DESeq2 package (38).
A gene was considered as differentially expressed between two
CD4+ subtypes if associated with an adjusted p < 0.001. To
transform the expression data in Z-score, first, the average
expression across the five RNA-Seq replicates of each CD4+
subtype, then the mean expression and the standard deviation
across the five CD4+ subtypes were computed.
Transcription Factor Binding Motif Analysis
A non-redundant list of human Positional Weight Matrices
(PWMs) was obtained from the integration of four public
PWM databases (HOCOMOCO v10, jolma 2013, CISBP v1.02,
Jaspar vertebrates 2016). PWM were selected based on species
and quality attributes. Firstly, only human- or mouse-derived
PWMs were selected favoring human-TF related matrices. Then,
PWMs derived from experimental evidence were preferred to
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computational inferred ones in case of PWMs concerning the
same TF.
TF motifs discovery at ARRs was performed using Find
Individual Motif Occurrences software (FIMO) included in
the MEME suite for Motif-based sequence analysis (39). A
significance threshold of 0.001 on the p-value score has been
applied for the motif finding analysis.
Network Reconstruction
Regulatory networks of Th17 and Treg cells were designed
considering subtype specific regulatory interactions. Specifically,
for each CD4+ subtype, network nodes represent expressed SE-
ARR associated genes. A gene was classified as TF using a list
of experimentally validated TFs from the Animal Transcription
Factor Database (40). Network edges represent regulatory
interactions predicted by motif finding analysis performed on
SE-ARR sequences using Find Individual Motif Occurrences
software (FIMO) included in the MEME suite (39). Then, node
inward links connect that node/target with its TF regulators
whose binding is predicted at node/target SE-ARRs. Conversely,
outward links represent regulatory interaction of a node/TF
with its targets by SE-ARRs binding. We called CSRs the
subset of SE-ARRs associated with highly differentially expressed
TFs between Th17/Treg cells and Naive T cells (DESeq2 FDR
adjusted p < 1.0 × 10−7). Thus, we filtered networks for CSRs,
obtaining core regulatory subnetworks. Pairwise gene expression
correlation analysis was performed using the 25 FPKM values
from CD4+ RNA-Seq analysis (E-MTAB-2319) (35). Pearson
linear correlation on each pair of genes was computed. An
absolute Pearson coefficient >0.3961 was considered statistically
significant for positive or negative correlations (two-tailed t-
test, p < 0.05). Positive and negative correlations were used to
represent activatory and inhibitory network links, respectively.
For network visualization, Cytoscape version 3.4.0 was used (41).
Network analyzer (42) was applied to compute network statistics.
Patients
Fifteen pregnant MS patients with clinically defined RRMS
(mean age 36 ± 4), referred to the academic neurological unit,
Department of Clinical and Biological Sciences, University of
Turin (IT); AOU Federico II, Regional Multiple Sclerosis Centre,
Naples (IT); and Multiple Sclerosis Center, ASST Ospedali Civili
di Brescia, Brescia (IT) were enrolled in the study. Inability
to express the informed consent, treatment with any RRMS
drugs (interferon beta 1a or 1b, glatiramer acetate, tecfidera,
teriflunomide, fingolimod, mitoxantron, alemtuzumab), alcohol
abuse, cardiopathies, major depression and the concomitance
with other autoimmune diseases were exclusion criteria. Fifteen
sex and age matched healthy donors, referred to City of Health
and Science Academic Hospital, Birth Center Sant’Anna, Turin
(IT), were enrolled as the control group. Demographical and
clinical characteristics of patients and HDs are outlined in
Table 1. Blood samples were collected during routine checkup
and processed within 24 h of collection. The institutional review
board of the participating centers approved the study design and
all subjects gave written informed consent.
TABLE 1 | Patients’ characteristics.
Clinical data HD RRMS
Mean age (years)a 32.3 ± 7.4 34.9 ± 4.7
Median EDSS before pregnancy – 2 (1–5.5)
Median number of relapses before pregnancy 2 (0–2.6)
Median number of relapses after delivery – 0 (2–0)
Mean number of therapies before pregnancy – 1.4 ± 1.09
aAge at T3.
PBMCs, Treg, and Th17 Cells Isolation
PBMCs were isolated from whole blood samples by a Ficoll-
Paque TM PLUS (GE Healthcare, Milan, IT) density-gradient
centrifugation. Treg cells were separated from PBMCs using
the CD4+CD25+CD127dim/– Regulatory T Cell Isolation Kit
II human (Miltenyi Biotec, GmbH, Germany). This separation
consisted in two steps. First, the isolation of CD4+ CD25+
CD127dim/– regulatory T cells was performed with a cocktail
of biotinylated antibodies and Anti-Biotin MicroBeads for the
depletion of non-CD4+ and CD127high cells by separation
over a MACS R© Column, which is placed in the magnetic field
of a MACS R© Separator (Miltenyi Biotec, GmbH, Germany).
In the second step, the flow-through fraction of pre-enriched
CD4+CD127dim/– T cells was labeled with CD25 MicroBeads
for subsequent positive selection of CD4+CD25+CD127dim/–
regulatory T cells. Negatively selected fraction of CD4+CD25–
T cells was collected for the next separation of Th17 cells. This
cell fraction was stimulated with 50 ng/ml Phorbol-12-myristate-
13-acetate (PMA) and 500 ng/ml Ionomycin (Sigma Aldrich) at
37◦C for 4 h to induce cytokines production. Th17 cells were
then separated using IL-17 Secretion Assay-Cell Enrichment and
Detection Kit human (Miltenyi Biotec, GmbH, Germany). PMA-
ionomycin stimulated cells were mixed with the provided IL-17
Catch Reagent and incubated for 45min at 37◦C to allow the
reagent to bind the positive, secreting cells. IL-17–secreting cells
were subsequently labeled with a second PE-conjugated IL-17–
specific antibody and finally magnetically labeled with Anti-PE
MicroBeads UltraPure and separated over a MACS R© Column.
In vitro Th17 Cells Polarization
Isolated PBMCs from female healthy donors (HD) (18–45 years
old) were cultured in RPMI 1640 medium containing 10%
estrogen deprived Fetal Bovine Serum (FBS), 2% HEPES, 1%
Glutamax, and 1% Gentamicin. They were activated with plate-
coated anti-CD3 (10µg/ml) and soluble anti-CD28 monoclonal
antibodies (mAbs) (1µg/ml; BD Biosciences, San Diego, CA) for
3 days in the presence of IL-23 (50 ng/ml; R&D Systems) plus
anti–IFNγ (100 ng/µl; Biolegend, San Diego, CA) as previously
described (3). At day 0, cells were treated with 17β-estradiol
(E2) 35 ng/mL or vehicle (ethanol) in concomitance with Th17
polarizing cytokines.
Flow Cytometry Analysis
PBMCs were stained for Treg cells with anti-CD4, anti-CD25,
and anti-CD127 mAbs (Biolegend, San Diego, CA) on the
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cell surface. For detection of the transcriptional factor FoxP3,
cells were fixed with Fixation and Permeabilization Buffers
(eBioscience, San Diego, CA) and were then stained with anti-
FoxP3 mAb (eBioscience, San Diego, CA). The expression of IL-
17 was analyzed by intracellular cytokine staining. PBMCs were
cultured in Iscove’s Modified Dulbecco’s Medium (BioWhittaker,
Walkersville, MD) supplemented with 10% Fetal Bovine Serum
(FBS, Invitrogen, Carlsbad, CA) and stimulated for 5 h with
Phorbol 12-myristate 13-acetate PMA (50 ng/ml) and ionomycin
(500 ng/ml) in the presence of Brefeldin A (BFA, 10µg/ml,
Sigma-Aldrich, St. Louis, MO). Cells were first stained for
the surface antigen CD4, (Biolegend, San Diego, CA) and
then fixed with 4% paraformaldehyde, permeabilized with 0.5%
saponin, followed by intracellular staining with anti-IL-17 mAb
(Biolegend). ERα expression on Th17 and Treg cells was detected
by staining with ERαmAb (LSBio, Seattle, WA). The ERα specific
cell-associated mean fluorescence (1MFI) was calculated by
subtracting theMFI of cells stained with control isotype IgG from
that of cells stained with ERamAb. Stained PBMCswere acquired
on a BD AccuriTM C6 Cytometer (BD Biosciences, San Jose, CA)
and analyzed with FlowJo software (Ashland, OR).
Chromatin Immunoprecipitation Assay
We adapted a ChIP protocol optimized for a small amount
of chromatin (43). PBMCs and purified Treg and Th17 cells
were incubated with 1% formaldehyde in PBS 1X for 10min at
37◦C. The crosslinking reaction was stopped by adding glycine
at a final concentration of 125mM followed by incubation
at room temperature (RT) for 5min. PBMCs nuclear extracts
were then obtained with a two-step lysis procedure using Cell
Lysis Buffer (5mM Pipes pH 8.0, KCl 85mM, NP40 0.5%) and
Nuclei Lysis Buffer (SDS 1%, EDTA 10mM, Tris-HCl pH 8.1
50mM) both added with 1X protease inhibitor cocktail (Sigma-
Aldrich) and 1mM phenylmethylsulfonylfluoride (PMSF, Sigma-
Aldrich). In the case of purified Th17 or Treg cells, only Nuclei
Lysis Buffer step was performed. Cell lysates were incubated
on ice for 10min and then sonicated in two different ways
according to the starting sample. Chromatin from PBMCs
was fragmented by 20 sonication cycles consisting of 20′′ on
and 50′′ off using Sonopuls HD2070 sonicator (Bandelin).
Th17 and Treg chromatin were fragmented for 30 pulses
30
′′
ON/30
′′
OFF high with Bioruptor Twin (Diagenode). A
small fraction of chromatin was decrosslinked with 50 µg
of Proteinase K (Thermo Fisher Scientific) and DNA was
purified with phenol chloroform (Ambion, Applied Biosystems),
followed by ethanol precipitation. Chromatin fragmentation
was checked by electrophoretic separation of DNA on a
1.2% agarose gel. One microgram of sonicated chromatin was
diluted in IP buffer to a final volume of 120 µl for each
immunoprecipitation, and incubated with 0.5 µg of antibodies
against human H3K4me3 (Diagenode), H3K27me3 (Active
Motif), H3K4me1 (Diagenode), H3K27ac (Active Motif), ERα
(HC-20) X, and ERα (H-184) X (Santa Cruz Biotechnology)
in a BSA precoated CorningTM FalconTM Polystyrene 96-well
microplate (Thermo Fisher Scientific). Lysates with Ab were
incubated at 4◦C overnight on an orbital shaker. Samples with
IgG antibody (Abcam) were run in parallel as negative controls.
The following day, 30 µl of 50% Protein A SepharoseTM 4 Fast
Flow (GEHealthcare) slurry was added and incubated for 2 h
at 4◦C to purify the immune complexes. Proteins and DNA
complexes non-specifically associated with beads were removed
by sequential washes with low-salt buffer (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mMTris-HCl pH8.0, and 150 mMNaCl),
high-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA,
20mMTris-HCl, pH 8.0, and 500mMNaCl), LiCl washing buffer
(0.25M LiCl; 1% deoxycholate sodium salt, 1mM EDTA, 10mM
Tris-HCl pH8.0, and 1% NP-40) and twice with Tris-EDTA
buffer (10mM Tris-HCl pH 8.0, 1mM EDTA). Samples were
maintained at 4◦C for 5min on an orbital shaker each wash.
The immunoprecipitated DNA-protein complexes were purified
by 10% Chelex R© 100 Resin (BIO-RAD) for 10min at 95◦C.
Proteins were digested incubating each sample with 20 µg of
Proteinase K (Thermo Fisher Scientific) for 30min at 55◦C and
then 10min at 95◦C to obtain Proteinase K inactivation andDNA
purification. The resulting purified DNA was used for following
qPCR analysis.
Total RNA Extraction
Total RNA was extracted using TRIzol R© Reagent (Invitrogen)
according to the manufacturer protocol. Concentration of RNA
in samples wasmeasured byNanoDrop 1,000 Spectrophotometer
(Thermo Fisher Scientific). Extracted RNA were then treated
with ezDNaseTM Enzyme (Thermo Fisher Scientific). DNA-free
RNA was reverse-transcribed into complementary DNA (cDNA)
with SuperScriptTM IV VILOTM Master Mix (Thermo Fisher
Scientific). Resulting cDNA was used for qPCR analyses.
Real Time Quantitative PCR
Real Time PCR was performed using 7300 Real Time
PCR System (Applied Biosystems) and the iTaq Universal
SYBR Green Supermix (Biorad) in 96-wells multiwell plates
(Applied Biosystems). FOXP3 and RORC mRNA expression was
determined using QuantiTect Primer Assays (QIAGEN, Hilden,
Germany). Relative quantification of mRNA was normalized
on 18 s mRNA level. ChIP signals were normalized on input
samples (10% of total chromatin used per IP) and expressed
as enrichment of specific binding over the control non-specific
IgG binding. Primers for ChIP-qPCR analysis of promoter and
enhancers were designed using Primer3Plus software. Designed
primer were tested with in silico PCR tool (https://genome.ucsc.
edu/) in order to check specificity of amplification during PCR
reaction and with AnnHyb software (http://bioinformatics.org/
annhyb/) to verify self-hybridization and dimer formation of
primers. Primers were synthesized by Bio-Fab Research (Rome,
Italy) (Table S3).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5
(GraphPad Software, San Diego, CA). Student’s t-test for paired
values and one-way analysis of variance (ANOVA) followed by
Bonferroni multiple comparison post-test, were used. P < 0.05
was considered to be significant.
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RESULTS
Definition of Active Regulatory Regions
Within Super Enhancers of CD4+ T Cell
Subtypes
Genomic regulatory regions are integrative hubs for cellular
pathways activated upon environmental stimuli. Since we were
interested in the identification of putative genomic targets of
estrogens signaling in Th17 and Treg cells, ERα modulated
chromatin regulatory hubs were identified by using an integrative
analysis of epigenomic and transcriptomic data. We designed
a computational approach composed of four consecutive Next
Generation Sequencing (NGS) data integration steps: (i) SEs
prediction in CD4+ T cell subtypes, (ii) chromatin states analysis
for identification of active regulatory regions, (iii) overlap
between these regions and SEs detected in Th17 and Treg cells,
(iv) reconstruction of a core TFs regulatory network of Th17 and
Treg cells and identification of putative ERα targets (Figure 1A).
We predicted SEs using public H3K27ac ChIP-Seq
data of human CD4+CD25–CD45RA+ cells (Naive T),
CD4+CD25– T cells (Th), CD4+CD25–IL17+ T cells (Th17),
and CD4+CD25+CD45RA+ T cells (Treg) from the Roadmap
Epigenomics Project (30), identifying 658, 676, 999, and 851 SEs
in Naive T, Th, Th17, and Treg cells, respectively (Figure 1B
and Table S1A). Interestingly, Gene Ontology (GO) analysis
of genes mapped in proximity of SEs showed an association
with “immune response” and “regulation of immune system”
processes (Table S1B). We also evaluated the enrichment of
Single Nucleotide Polymorphisms (SNP) associated to a set of
41 diseases, within Th17 and Treg SEs. Autoimmune-disease-
associated SNPs, overlapped more often with Th17 and Treg
SEs than with a random set of regions of the same length. This
enrichment is stronger for autoimmune-disease-associated SNPs
in respect to the control group of other-disease-associated SNPs
(Figure S1A).
To identify Active Regulatory Regions (ARRs) in SEs of Th17
and Treg cells, we analyzed chromatin states data predicted by
ChromHMM (44) in the aforementioned CD4+ T cell subtypes.
This model consists of 25-chromatin states model based on
imputed data for 12 epigenetic marks defined for 127 cell types
and provides a 200 bp human genome segmentation with the
corresponding predicted functional annotation. Using this data,
we selected a subset of 65,581 genomic regions characterized
by an enrichment of H3K27ac and lysine 4 mono-methylation
of histone H3 (H3K4me1) whose co-occurrence defines active
enhancers (45). To distinguish these regions according to their
level of regulatory activity among CD4+ T cells, we compared
their epigenetic state (see Methods for details) and found 4,610
(7.03%), 7,508 (11.45%), 4,720 (7.20%), and 5,608 (8.55%) ARRs
exclusive to naive T, Th, Th17, and Treg cells, respectively
(Figure S1B and Table S1C). Then, to further isolate ARRs
characterized by the highest predicted regulatory activity, we
overlapped ARRs with predicted SEs in these cell subtypes.
The 2.27, 2.73, 14.60, and 8.10% of naive-, Th-, Th17-, and
Treg-ARRs, respectively, overlapped with SE regions (Figure 1C
and Table S1D). As expected, SE-overlapped ARRs (SE-ARRs)
showed significantly higher levels of H3K27ac compared with
ARRs (Figure 1D). Moreover, the comparison of Th17 and
Treg SE-ARRs underlines that H3K27ac in SE-ARRs has a
cell-type specific enrichment (Figure 1E). Gene Ontology (GO)
analysis for genes mapped in proximity of Th17 SE-ARRs
showed an association with immune system and inflammatory
processes, whereas Treg SE-ARRs are associated with chromatin
remodeling and metabolism (Figure 1F and Tables S1E,F).
Reconstruction of Cell Type-Specific
Regulatory Networks Identifies
ERα-Regulated Genomic Regulatory
Regions in Th17 and Treg Cells
In order to obtain an overview of gene expression profiles
associated to SE-ARRs in Th17 and Treg cells, we re-analyzed
raw data from a paired-end tag poly (A+) RNA-Seq datasets
performed on purified CD4+ T cells, including Th17 and Treg
cells, from five human healthy donors (35). We found 1,291
significantly Differentially Expressed (DE) genes between Th17
and Treg cells, 147 of which associated to SE-ARRs mapped
within a distance of 100 kbp (Figure 2A and Table S2A).
Comparison of the expression specificity among CD4+ T cells
highlighted that upregulated genes in Treg cells were more
specific of this CD4+ subtype, while upregulated genes in
Th17 cells were similarly expressed in Th1 and Th2 subtypes
(Figure 2B). Interestingly, among these genes, the highest DE
TF-coding genes associated with SE-ARRs were RORC, HSF4,
and MAF in Th17 cells, and IKZF2, FOXP3, and IKZF4 in Treg
cells (Table S2A).
To identify putative regulatory interactions between SE-
ARRs associated TFs, we explored the sequence of SE-ARRs
for the binding motif of a list of human TFs (see Methods
for details). Results of this analysis were used to reconstruct
a core TF regulatory network in which the indegree of nodes,
representing TF-coding genes, is given by the number of
significant TF binding motifs enriched at gene-associated SE-
ARRs. Conversely, the outdegree of nodes is the sum of
predicted TF bindings to other gene-associated SE-ARRs (46)
(Figure S1C). We extracted information on key candidate TFs
involved in Th17 or Treg lineage determination by computing the
differential gene expression between Th17/Naive and Treg/Naive
CD4+cells. We identified 4 and 10 SE-ARR-associated DE
TFs (FDR adjusted P < 1.0 × 10−7) in Th17/Naive and
Treg/Naive comparison respectively (Tables S2B–E). We used
these TFs to create subnetworks of the total regulatory networks
(Figures 2D,E). Then, we enriched these subnetworks with
activation and inhibition regulators inferred by a correlation
analysis of gene expression (Figures 2D,E and Table S2F). Our
network reconstruction highlighted RORC, MAF, and HSF4 as
nodes with highest indegree in the Th17 network, and FOXP3,
IKZF2, IKZF4, PRDM1, and SATB1 as core regulated genes in
Treg cells (Figures 2D,E).
Interestingly, the subset of SE-ARRs associated with these
DE TFs show a cell-type specific enrichment of epigenetic
marks associated with active enhancers. Hierarchical clustering
analysis of single histone modification within these SE-ARRs
discriminates the different CD4+ T cells subtypes (Figure 2C).
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FIGURE 1 | Active regulatory regions within super enhancers of CD4+ T cell subtypes (A) Workflow representation of our approach for data integration. SEs
prediction in CD4+ T cell subtypes and chromatin states analysis were used for identification of active regulatory regions (left side). Overlap between these regions
defines SE-ARRs. DE Gene expression analysis led to the identification of main TFs involved in Th17 and Treg lineage determination (right side). Finally, we
reconstructed a SE-ARRs-associated TFs regulatory network in Th17 and Treg cells. By this analysis, we identified putative targets of ERα-mediated regulation in
Th17 and Treg cells. (B) Prediction of SEs in Th17, Treg, Naive T, and Th cells by Rank Ordering of Super Enhancers (ROSE) algorithm. Line plot reports the
cumulative number of enhancers identified in Th17 and Treg cells as function of the number of H3K27ac ChIP-Seq reads over the input dataset. Vertical lines
represent the threshold over which H3K27ac signal intensity defines SEs. (C) Bar plot shows the fraction of ARRs overlapping SEs in Th17 and Treg. (D,E) Box plot
shows the log2 normalized H3K27ac, H3K4me1, H3K27me3, and H3K9me3 ChIP-Seq signal measured in Th17- (D) and Treg- (E) SE-ARRs. On right panels
SE-ARRs comparison with ARRs. P-value by Wilcoxon Rank-sum test. (F) Bar plot shows top 15 most significant Gene Ontology Biological Processes enriched by
Genomic Regions Enrichment of Annotations Tool (GREAT) for genes mapped in proximity of Th17 (left) and Treg (right) SE-ARRs.
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FIGURE 2 | ERα-regulated genomic regulatory regions inTh17 and Treg cells. (A) Heat map representing the log2FC of expression computed between Th17 and Treg
RNA-Seq data. Only data of SE-ARRs associated significantly DE genes between the two CD4+ cell type are reported. Genes are sorted by decreasing Th17/Treg
log2FC. (B) Heat map representing the gene expression specificity computed in each CD4+ population as Z-score of expression. Purple colors represent specifically
overexpressed genes while green color specifically underexpressed genes. (C) Heatmap shows log2 normalized H3K27ac, H3K4me1, H3K27me3 and
(Continued)
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FIGURE 2 | H3K9me3 ChIP-Seq signal measured in CSRs associated nodes from Th17 and Treg core regulatory networks. Hierarchical clustering shows differences
between the epigenetic asset of Treg- and Th17- CSRs. (D,E) Th17 (D) and Treg (E) core regulatory networks. Core regulatory networks are reconstructed by filtering
total regulatory networks for SE-ARRs associated TFs with a significant fold change (DESeq adjusted p-value <1 × 10−7). Node size is scaled to indegree values.
Node color represents log2 fold change expression of Th17/Naive CD4+ cells and Treg/Naive CD4+ cells, respectively. Edge thickness is scaled to the sum of
predicted TF binding sites at target-associated CSRs. Edge color represents positive (green) or negative (red) regulation inferred by Pearson correlation analysis
between regulator and target gene expression. Positive and negative correlations are used to represent activatory and inhibitory network edges, respectively. Since
PWMs are not available for all TFs, some interactions could not be predicted. (F,G) Networks show predicted ERα binding at SE-ARRs associated TFs in Th17 (F) and
Treg (G) cells. Edge thickness is proportional to the number of ERE identified at target SE-ARRs. Node color represents log2 fold change expression of Th17/Naive
CD4+ cells and Treg/Naive CD4+ cells, respectively. Node size is fixed. ERα targets included also in respective core regulatory network are highlighted with a gray
circle.
Hence, we called these regions Cell-type Specific Regulatory
regions (CSR).
Finally, since our main interest was to identify targets for
genomic pathway of estrogens, we sought for the enrichment
of estrogen response elements (ERE) within Th17 and Treg SE-
ARRs. We found an enrichment of ERE in SE-ARRs associated
to 46 TFs identified in Th17, and to 65 TFs in Treg cells. Among
these TFs, 9 and 15 are DE (FDR adjusted P <1.0 × 10−3) in
Th17/Naive and Treg/Naive cells, respectively (Figures 2F,G and
Tables S2G,H).
Collectively, this analysis shows CSR-associated TFs in Th17
or Treg cell differentiation. Moreover, it revealed RORC and
FOXP3 as first major candidates of ERα-mediated regulation.
E2 Impairs Th17 in vitro Polarization
Inducing Chromatin Remodeling at FOXP3-
and RORC-CSRs
To understand the effects of E2 on Th17 cells during pregnancy,
we activated peripheral blood mononuclear cells (PBMC) from
female healthy donors (HD) in vitro under Th17 polarizing
conditions in the presence and absence of E2 at pregnancy
concentration (35 ng/ml). Figure 3A shows FOXP3 and RORC
loci, with associated CSRs derived from previously described
bioinformatic analysis. We designed primers within these
regions, and in two other biologically relevant regions: FOXP3
intronic Conserved non-coding sequence 2 (CNS2) (47) and
RORC promoter.
Chromatin immunoprecipitation assay followed by qPCR
(ChIP-qPCR) was performed against typical histone marks of
promoters and enhancers and ERα binding. At RORC locus, E2
treatment increases H3K27me3 enrichment at gene promoter
and ERα binding at the enhancers, whilst decreasing H3K4me1
levels at the enhancer (Figure 3B). By contrast, at FOXP3 locus,
E2 treatment increases H3K4me3 enrichment at gene promoter,
H3K4me1 and H3K27ac enrichment at the enhancers and the
binding of ERα in all of the tested regions (Figure 3C). The
epigenetic changes induced by E2 treatment at FOXP3 and RORC
loci reflect an enhanced FOXP3 and an impaired RORC mRNA
expression (Figure 3D). Consistently, E2 treatment induces a
significant inhibition of Th17 cells expansion and a slight
increase of Treg cells that return to similar levels to those before
polarization (Figure 3E).
Altogether, these data indicate that E2 treatment impairs Th17
expansion and induces a chromatin remodeling at CSRs involved
in Th17 and Treg subtype definition.
Pregnancy-Associated Epigenetic
Signature at CSRs in Th17 and Treg Cells
of MS Patients
Fifteen pregnant RRMS patients and fifteen pregnant healthy
donors (HD) were studied during the third trimester of
pregnancy (T3) and the postpartum period (pp). The
epidemiological and clinical characteristics of these subjects
are summarized in Table 1. In the peripheral blood, we observed
a significant reduction of Th17 cells in the T3 (0.45%± 0.06) and
in the pp (0.73% ± 0.19) compared with active non-pregnant
RRMS (2.6% ± 0.56), whereas no difference was detected in
HD (Figure 4A). Treg cells increase significantly in the T3 both
in HD (3.42% ± 0.23) and in RRMS (2.86% ± 0.43) compared
with non-pregnant HD (1.9% ± 0.24) and active RRMS (1.27%
± 0.17, Figure 4B). Interestingly, CD4+ T cells from RRMS
patients expressed significantly higher levels of ERα compared
with HD (Figure 4C), and this feature was peculiar of Th17
cells but not of Treg cells, as ERα was expressed at the same
level both in Treg cells from HD and RRMS (Figure 4D). These
data suggest that estrogens may affect circulating CD4+ T cells,
especially Th17 cells in RRMS.
To understand if chromatin remodeling occurs in
lymphocytes from RRMS patients during pregnancy, RORC
and FOXP3 CSRs were tested for histone marks and ERα binding
in PBMCs derived from RRMS patients during T3 and pp.
At RORC promoter, ERα binding is higher during T3 and
correlates with a higher H3K27me3 and a lower H3K4me3
during T3. During pp, we observed an increment of ERα binding
at RORC-associated enhancer, going on with higher H3K4me1
and H3K27ac enrichment (Figure 4E). ERα binding at FOXP3
promoter and enhancers is higher in T3 compared with pp.
This goes along with H3K4me3 increment at the promoter
and H3K4me1 and H3K27ac enrichment at the enhancers
of FOXP3 during T3 compared with pp. Simultaneously, the
fall of ERα binding during pp is associated with a higher
H3K27me3 enrichment at FOXP3 promoter (Figure 4F). None
of these epigenetic changes occurs at RORC (Figure 4G) and
FOXP3 (Figure 4H) CSRs in PBMCs derived from HD. These
results suggest a MS specific epigenetic profile characterized by
activation of FOXP3CSRs and inactivation of RORCCSRs during
T3 and by the activation of RORC CSRs and the inactivation of
FOXP3 CSRs during the pp.
To better clarify in which cell type these epigenetic variations
occur, we tested the epigenetic changes in all the selected
FOXP3 and RORC CSRs in purified Th17 and Treg cells from
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FIGURE 3 | E2 impairs Th17 polarization inducing chromatin remodeling at CSRs. (A) UCSC Browser of human FOXP3 locus and RORC locus. First colored bars
represent the chromatin states (e.g., yellow segments are classified as active enhancers). Blue bars are predicted SEs, purple bars are ARRs and green bars are the
regions that we analyzed. (B–E) PBMCs from five HD were polarized under Th17 polarizing conditions with or without E2 treatment. ChIP-qPCR analysis of
H3K4me3, H3K27me3, H3K4me1, H3K27ac, and ERα at RORC- (B) and FOXP3- (C) CSRs. Columns represent the enrichment of the immunoprecipitation over
non-specific IgG and normalized for input chromatin at 30min and 3 days of stimulation. FOXP3 and RORC mRNA expression (D), and FACS analysis of Th17 and
Treg cells in CD4_lymphocytes (E) stimulated for 3 days. *p < 0.05, **p < 0.01, and ***p < 0.001 represent the statistical significance.
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FIGURE 4 | Epigenetic changes at FOXP3 and RORC loci in PBMCs from MS patients during pregnancy. (A,B) Th17 and Treg cells percentage, evaluated by FACS,
in the PBMCs of HD (gray bars) and MS patients (white bar) non-pregnant, during the T3 and in the pp. (C,D) Expression of ERα, evaluated by FACS, on total CD4+ T
cells, Th17, and Treg cells from HD and MS patients. Graph shows ERα specific cell-associated mean fluorescence (1MFI). (E–H) ChIP-qPCR analysis of H3K4me3,
H3K27me3, H3K4me1, H3K27ac, and ERα binding on PBMCs derived from MS patients (E,F) and HD (G,H) during T3 and in the pp. Boxes, with mean, minimum
and maximum, represent the enrichment of the immunoprecipitation over non-specific IgG and normalized for input chromatin. *p < 0.05, **p < 0.01 and
***p < 0.001 represent the statistical significance.
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6 RRMS pregnant patients during T3 and pp. In purified
Th17 cells, we observed an enrichment of H3K4me3 at RORC
promoter and H3K4me1 at the enhancer in the pp suggesting
activation of RORC (Figure 5A). Surprisingly, we observed the
same epigenetic variations at RORC locus in purified Treg
cells (Figure 5A). In this subtype, the enrichment of H3K4me1,
H3K27ac, and a higher ERα binding at FOXP3 enhancers
were observed during T3, whereas H3K27me3 level at FOXP3
promoter increase in the pp, indicating activation of FOXP3
during T3 and its inactivation during pp (Figure 5B). The
activation of FOXP3 during T3 correlates with higher binding
of ERα at FOXP3 enhancers. Once again, the same variations
were observed at FOXP3 locus in Th17 cells (Figure 5B). The
observation of the same epigenetic variation in both Th17 and
Treg cells suggest a mutual plasticity of these cells that could be
regulated mainly by estrogens.
Overall, epigenetic analysis of PBMCs and purified Th17 and
Treg cells indicate that FOXP3 CSRs were activated while RORC
CSRs were inactivated during T3 of RRMS patients.
DISCUSSION
Despite the numerous evidence that estrogen has beneficial
effects on the clinical signs of MS and EAE and the emerging
results of which are E2-responsive target cells in the EAE (10,
48, 49), little is known about the molecular signaling above
E2. In this study, we identified a peculiar epigenetic profile of
Th17 and Treg cells of MS during pregnancy that could be
associated to ERα activation. ERα expression and signaling in
encephalitogenic CD4+ T cells was reported to be required
for sustained EAE protection (10). Here, we show that RRMS
CD4+ T cells, and in particular Th17 cells, express higher
levels of ERα, making them supposedly more responsive to
estrogen level variations. This could be considered a peculiar
characteristic of pathogenic Th17 cells of MS patients that, as
broadly demonstrated, display a typical expression of cytokines,
chemokines, transcription factors and membrane receptors that
are characteristics of pathogenic Th17 cells but not of Th17 cells
involved in the response to pathogens (50). In the EAE model,
Th17 cells were shown to be a target for E2 that resulted in
the inhibition of encephalitogenic Th17 cells expansion (51);
the mechanisms of this anti-inflammatory effects of E2 involved
both by a direct action on Th17 cells (10) and the expansion of
Treg cells (13, 15), induction of tolerogenic dendritic cells and
recently, regulatory B cells (52). Similar to the EAE model and
previous MS studies (53, 54), here we show that in the T3 of
pregnancy, where estrogens reach the highest levels, Th17 cells
strongly decreased, whereas Treg cells increased; such results
could be indicative of a less inflammatory environment in MS
patients during pregnancy.
From clinical point of view, pregnancy is accepted to be a
period in which relapses decrease significantly, especially in the
third trimester as explored in several clinical studies (6, 7, 55, 56).
From an immunological point of view, Immune system is not the
main target for sex hormones, however the high level of estrogens
during pregnancy exerts its role on immune system adaptation
contributing to immunotolerance, such as hematopoietic and
Treg cells proliferation (57, 58). On the contrary, the postpartum
phase is characterized by a strong drop in estrogens level, with
immunomodulation lost (59). These two phases represent a
unique opportunity for comparison, as pregnancy maximizes
the immune cell subtypes differences between third trimester
and post-partum resembling, respectively, remission and relapse
phases of MS disease. Pregnancy immunotolerance in MS, with
a dominance of Treg cells over Th17 cells respect to postpartum
is associated with the physiological immunotolerance
(53, 60).
Although Th17 and Treg cells represent two CD4+ T cell
subsets with opposing principal functions, these cell types
are functionally connected; for example, TGF-β links the
development of Th17 cells to that of Treg cells: TGF-β indeed
induces the differentiation of Treg cells but in combination with
IL-6 or IL-21 promotes the induction of Th17 cells and inhibit
Treg cells differentiation (61). At the molecular level, FOXP3, the
master regulator TF of Treg cells, could bind physically to RORC,
the master regulator TF of Th17 cells, to antagonize its function
(62). Furthermore, other factors, such as retinoic acid (RA),
aryl hydrocarbon receptor (AHR) or hypoxia inducible factor
1α (HIF-1α) can regulate the balance between Th17 and Treg
cells (63). Plasticity has been observed between both antagonistic
cell type: Th17-like Treg cells, i.e., FoxP3 Treg cells also
expressing IL-17, has been reported (64, 65) and seems to depend
on epigenetic modifications (66). The role of the chromatin
landscape is indeed important in the context of TF action and
cellular plasticity, as the chromatin state deeply influences TF
binding. Here, by using a bioinformatics integrative approach,
we selected the putative genomic regulatory regions that may
be a target for ERα signaling in the epigenetic control. The
observation that the same epigenetic variation occurs in both
purified Th17 and Treg cells suggests a mutual plasticity of these
cells that could be regulated mainly by estrogens.
ERα cistrome has been extensively studied in breast and
endometrium: genome wide data sequencing of ERα binding,
integrated with epigenetic marks and chromatin long range
interactions data allow for the prediction of ERα action. One
of the most important results derived from integrative analysis
in breast cancer experimental models is that EREs and ERα
binding are enriched at SEs (67). Furthermore, the crosstalk
between ERα and inflammatory signaling plays a role in the
endocrine resistance of breast carcinoma. ERα phosphorylation
and cofactor recruitment by cytokine stimulation induces a
constitutive ERα-dependent activation of gene expression and
proliferation that is involved in cancer progression and resistance
to endocrine therapy (68, 69). ERα, bound to DNA at distal
genomic regulatory regions of target genes, interacts with
transcription factors and recruits coactivators or corepressors
that mediate the association with enzymes able to remodel
chromatin (70). Orchestrating chromatin architecture, ERα may
mediate epigenetic modifications at chromatin hubs in CD4+ T
cells, influencing their differentiation and plasticity, as well as
it does in its main target tissues. On this way, ERα may act as
cooperative transcription factor in T cell epigenome dynamics for
the environment adaptation (71).
Frontiers in Immunology | www.frontiersin.org 12 January 2019 | Volume 9 | Article 3075
Iannello et al. Epigenetic Signature of MS Pregnancy
FIGURE 5 | Epigenetic changes at FOXP3 and RORC loci in Treg and Th17 purified from MS patients during pregnancy. ChIP-qPCR analysis of H3K4me3,
H3K27me3, H3K4me1, H3K27ac, and ERα binding performed at RORC- (A) and FOXP3-CSRs (B) in Th17 (red) and Treg (blu) cells, derived from MS patients during
third trimester of pregnancy T3 (filled texture) and during the post-partum pp (squared texture) phase. Boxes, with mean, minimum and maximum, represent the
enrichment of the immunoprecipitation over non-specific IgG and normalized for input chromatin. *p < 0.05 and **p < 0.01 represent the statistical significance.
Next Generation Sequencing data allow the capture of
different -omics information, and multilevel studies integration
can provide an upgrade of knowledge about immune system
cells. Integrative data analysis confers novel functions to
specific genomic regions that are hubs of gene regulatory
circuitry by recruiting transcriptional complexes. Molecular
mechanisms underlying transcriptional regulation guided our
integrative analysis of epigenomic and transcriptomic data.
On these bases, we reconstructed a regulatory network in
human Th17 and Treg cells, highlighting CSR-associated
TFs that cooperate for cell identity determination. Network
reconstruction has already been explored in Th17 mouse cells
combining -omics data integration with KO or innovative
perturbation tools (23, 72). Recently, even single-cell RNA-Seq
has been used to investigate molecular mechanisms governing
heterogeneity and pathogenicity of Th17 cells (73). Regarding
Treg cells, network analysis approach has, to date, never been
explored.
Concerning Th17 cells, our core regulatory network shows
similarities with previously mentioned mouse networks. The
three upregulated TFs that stand out from our network are
RORC, MAF, and HSF4. RORC is the master regulator of
the Th17 lineage. It has yet been shown that E2 recruits a
repressor on RORC promoter EREs via ERα, thus inhibiting
RORC expression and Th17 differentiation (48). The role ofMAF
in Th cells and autoimmunity has been extensively explored.
Gustafsson et al. proposed MAF, together with GATA3 and
MYB as early regulators of T cell–associated diseases (74). These
TFs are enriched in autoimmunity-associated polymorphisms
and DE between Th1 and Th2 subtypes at early stages of
differentiation. In addition, they show DE of splice variants
during asymptomatic and symptomatic stages of seasonal allergic
rhinitis. A MAF-associated long intergenic non-coding RNA
(linc)-MAF-4 regulates MAF transcription by exploiting a
chromosome loop with the promoter of MAF and its expression
shift Th cells differentiation alternately toward Th1 or Th2
subtype (35). c-MAF was also identified in the complex network
of TFs regulating Th17 cells as fundamental for the development
of memory Th17 cells (75). HSF4 is one of the heat shock
transcription factors that are involved in the suppressive function
and cytokine production of Treg cells (76).
Concerning Treg cells, the comparison with literature
highlighted some known Treg specific TFs, such as FOXP3,
IKZF2, and IKZF4. FOXP3 is the master regulator of Treg
cell identity and regulates Ikaros family members, such as
IKZF2-4 (77), characterized as DNA binding proteins containing
two zinc finger N-terminal domains (highly conserved) and
protein binding domain (C-terminal). IKZF2, called Helios, is
highly expressed in Treg cells and, by binding at its promoter,
upregulates FoxP3 expression. Recently, lower Helios expression
was detected in Treg cells from clinically isolated syndrome
patients suggesting a less regulatory function (78). IKZF4, called
Eos, facilitates FOXP3-mediated gene silencing in Treg cells (79).
Genes that are associated with Treg-CSRs belonged to GO
categories related with chromatin remodeling and metabolic
processes. The link between core regulatory regions with cluster
of genes, that control cell metabolism, open a suggestive view
of Treg plasticity dependent on metabolic shift. Indeed, Treg
cells exhibit unique metabolic activities, characterized by low to
modest glycolysis and elevated mechanistic target of rapamycin
activity and nutrient metabolism, and these Treg-intrinsic
metabolic pathways program Treg generation and activity. Treg
cells have their own signaling and metabolic “preferences” that
can drive and dictate their function and stability (80). Even
more interestingly, genes associated with Th17-CSRs belonged
to GO categories related with regulation and activation of
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immune response. This result perfectly matches with Th17
specific functions.
Here we focused our attention on CSRs associated with
RORC and FOXP3, lineage- determining transcription factors
that play a critical role in Th17 and Treg cell fate. Selected
RORC associated CSRs included its promoter and an associated
enhancer. RORC promoter was included in our analysis because
of its biological relevance in transcriptional regulation of RORC.
FOXP3-CSRs, instead, partially overlapped with conserved
non-coding sequences (CNS). Foxp3-CNSs are three intronic
enhancers identified at Foxp3 gene locus, important for Treg
cell. Epigenetic modifications at these regulatory regions are
associated with Treg differentiation and functions (47).We found
that RORC-CSRs and FOXP3-CSRs are ERα target in human
PBMCs under Th17 polarization conditions and in PBMCs,
Treg, and Th17 from MS patients. During Th17 polarization
in presence of E2, we observed the enrichment of ERα binding
at FOXP3-CSRs and at RORC-CSRs; these data go along with
the enrichment of active marks at FOXP3-CSRs and repressive
marks at RORC promoter, and with the enhanced FOXP3 and
reducedRORC expression. These epigenetic changes overlap with
those that occur in PBMCs, and in purified Th17 and Treg cells
during T3 in MS patients, where E2 reaches the highest levels.
Altogether, these data suggest that ERα may induce chromatin
remodeling by acting in opposite manners at two different loci
(81). This effect could be ascribed to the recruitment of the
different proteins in the regulatory complexes that may involve
ERα as a key player for the switch between Th17 and Treg
cells (23). It is plausible that during pregnancy, the gradual and
continuous exposure to high levels of estrogen, can act both in the
prevention of differentiation or in transdifferentiation processes.
Of particular interest was the observation that epigenetic
modifications on RORC and FOXP3 loci occurs, not only at
their promoters, but also at their enhancers. Studies aimed at
the pharmacological targeting of epigenetic mechanisms made
the exciting observation that SEs are particularly vulnerable to
various inhibitors of transcriptional activation (82–84). Indeed,
treating human CD4+ T cells from healthy controls with the
JAK inhibitor tofacitinib selectively targeted rheumatoid arthritis
risk genes controlled by SEs (85), while exposure of CD4+ T
cells from Juvenile idiopathic arthritis (JIA) patients to the BET
protein inhibitor JQ1 preferentially inhibited JIA-specific super-
enhancer driven gene expression. BET protein inhibition was
also shown to selectively block human Th17 differentiation and
protect mice from experimentally induced autoimmunity (86).
The identified SE at RORC and FOXP3 together with other TF
identified in our analysis need to be deeply investigated and could
be used, in the future, as “epigenetic drugs” for MS disease.
Important limitations of this study include the small amount
of Th17 and Treg cell samples derived from MS patients
during pregnancy. Our results show that Th17 cells percentage
during pregnancy is reduced respect to MS active state and
this is a peculiar feature of MS disease because higher
Th17 cells levels mark the pathological condition and are
instead absent in healthy donor, as we previously showed
(3). Treg cells percentage increased in both MS patients and
healthy donors during pregnancy, respect to non-pregnant
state. Our results were expected for flow cytometry analysis, in
addition we performed histone marks analysis at the FOXP3
genomic regulatory regions, partially overlapped with CNS
regions associated with autoimmunity (47). Treg cell features
in MS patients are associated with proliferation rate and
cytokines expression dysregulation, and these alterations can
emerge during pregnancy (87–89). We found that epigenetic
modifications in pregnancy changed between T3 respect to PP
in MS patients, but not in healthy donors. These results not
completely explain the difference observed for Th17 and Treg cell
levels. To address this point further analyses are necessary; single
cell data- sequencing approach could reveal pathological state
features linking surface- antigenmakers with genomic, epigenetic
and gene expression profiles.
In summary, here, we show that Th17 and Treg cells from
pregnantMS patients have a peculiar epigenetic profile that could
be associated with ERα-mediated estrogen effects. Pregnancy
and autoimmunity are, indeed, challenging situations for the
immune system. Treg and Th17 cells play a dominant role
in both, although with opposing profiles: Treg cells activation
ensures pregnancy success; in parallel, Th17 cells are important
players in the development and progression of autoimmune
diseases such as MS. Therefore, pregnancy condition mimics
the pathological change of the balance between Treg and Th17
cells that occurs during relapsing- remitting disease course. This
study offers an initial molecular understanding of the regulatory
mechanisms ensuing during pregnancy and the identified CSRs
may represent potential biomarkers for monitoring disease
activity and progression or new potential therapeutic targets.
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